Shares of Biocon, a pharmaceutical company, rose by as much as 2% on Tuesday, 25 February, after Biocon Biologics, a fully integrated global biosimilars company and Biocon subsidiary, announced that Yesintek (ustekinumab-kfce) is now available to patients in the United States.
Read More
